Biotin Supplementation Ameliorates Murine Colitis by Preventing NF-κB Activation: Biotin supplementation ameliorates colitis.
Biotin is a water-soluble vitamin that is indispensable for human health. Biotin deficiency can cause failure-to-thrive, immunodeficiency, alopecia, dermatitis and conjunctivitis. We have previously reported that biotin deficiency can also lead to severe colitis in mice which is completely reversed with supplementation. Our aim in this study was to determine if high-dose biotin supplementation can provide a therapeutic benefit in a preclinical model for Inflammatory Bowel Disease (IBD) and to identify the molecular mechanism by which this occurs. Mice were challenged with Dextran Sodium Sulfate (DSS) to induce colitis and were treated with 1mM biotin to induce or maintain remission. Clinical response was monitored by Disease Activity Index (DAI) and fecal calprotectin. The colon tissue was investigated for histology, length, as well as expression of inflammatory cytokines (IL-6, TNF-α, IL-1β), intestinal permeability, tight junctions (Zo-1 and Claudin-2) and the transcription factor NF-κB. Biotin therapy led to delayed onset and severity of colitis as well as accelerated healing. There was improvement in DAI, fecal calprotectin, colon length and histology. Additionally, biotin-treated mice had reduced expression of inflammatory cytokines, reduced intestinal permeability and reduced activation of NF-κB. Oral supplementation with biotin provides benefit for maintenance and induction of remission in the DSS preclinical model for IBD. Biotin does this by reducing the activation of NF-κB which prevents production of inflammatory cytokines and helps maintain integrity of the intestinal barrier. Clinically, the NF-κB pathway is important in the development of IBD and this finding suggests that biotin may have therapeutic potential for patients with IBD.